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Abstract
Background: Few overlap between independently developed gene signatures and poor inter-
study applicability of gene signatures are two of major concerns raised in the development of
microarray-based prognostic gene signatures. One recent study suggested that thousands of
samples are needed to generate a robust prognostic gene signature.
Results: A data set of 1,372 samples was generated by combining eight breast cancer gene
expression data sets produced using the same microarray platform and, using the data set, effects
of varying samples sizes on a few performances of a prognostic gene signature were investigated.
The overlap between independently developed gene signatures was increased linearly with more
samples, attaining an average overlap of 16.56% with 600 samples. The concordance between
predicted outcomes by different gene signatures also was increased with more samples up to
94.61% with 300 samples. The accuracy of outcome prediction also increased with more samples.
Finally, analysis using only Estrogen Receptor-positive (ER+) patients attained higher prediction
accuracy than using both patients, suggesting that sub-type specific analysis can lead to the
development of better prognostic gene signatures
Conclusion:  Increasing sample sizes generated a gene signature with better stability, better
concordance in outcome prediction, and better prediction accuracy. However, the degree of
performance improvement by the increased sample size was different between the degree of
overlap and the degree of concordance in outcome prediction, suggesting that the sample size
required for a study should be determined according to the specific aims of the study.
Background
Recent advances in various high-throughput technologies
including genome sequencing, transcriptomics, genome-
wide SNP analysis, proteomics, glycomics, and metabo-
lomics have opened up new opportunities for developing
prognostic and predictive markers for better treatment of
diverse diseases. Indeed, many researchers have reported
promising results for improved patient treatment by pro-
viding more accurate prognostic and predictive informa-
tion for decision making [1-3]. Among various high-
throughput technologies, microarray gene expression pro-
filing has been widely used for prognostic and predictive
marker development for its rich information. The use of
gene expression profiling has particularly been wide-
spread in cancer research and now a few products are
already in market for clinical use and there are also a few
large scale clinical trials to determine the effectiveness of
gene expression profiling as a prognostic marker for can-
cer patients [2,4-7].
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While many researchers have shown promising results on
the possibility of gene expression profiling as a prognostic
marker, there are also concerns on the hasty use of the
technology in the clinic because many issues remain unre-
solved and some promising research results were pre-
sented in an over-optimistic and flawed manner [8-10].
Unresolved issues include the instability of identified
prognostic gene signatures, few overlap between inde-
pendently developed prognostic gene signatures, and
poor inter-study applicability of gene signatures
[9,11,12]. Here, the instability represents a phenomenon
in which prognostic signatures strongly depend on the
selection of patients in random sampling processes [9].
Genes repeatedly selected during random sampling are
defined as robust here.
Among the above-listed problems, the instability and few
overlap of already reported prognostic signatures have
received great attention. At first, the few overlap between
independently developed gene signatures was attributed
to the differences in patients, microarray platforms, or
applied statistical analyses. However, Ein-Dor et al.
showed that many equally efficient but non-overlapping
prognostic gene signatures can be identified from a single
data set because gene expression data contains numerous
informative genes [11]. Michiels et al. showed that only a
few genes are consistently selected from a given data set
when they applied random sampling approach in their
analysis [9]. To understand the nature of the instability of
prognostic gene signatures, Ein-Dor et al. developed a new
mathematical model and concluded that at least thou-
sands of samples are needed to develop a stable gene sig-
nature [12].
Currently, most gene expression profiling studies have
been performed with some tens to hundreds of samples.
Meta-analysis, by combining the results of several studies,
makes it possible to overcome the limits of many small
sample-sized studies. In this work, we pooled eight large-
scale gene expression studies to attain a data set with more
than 1,300 samples. Specifically, we only used data sets
produced using a single microarray platform, Affymetrix
U133A, in pooling different data sets to exclude data loss
and confounding factors arising from the combination of
different microarray platforms. Using more than 1,300
samples, we performed several analyses to understand the
various aspects of prognostic gene signatures.
Results
Construction of a single data set by pooling eight data sets
To understand the effects of a sample size on the classifier
performances, we first constructed a single data set by
pooling eight publicly available breast cancer data sets
(Table 1; [13-21]). Several methods including simple
mean-centering [22], distance weighted discrimination
[23], and empirical Bayes methods [24] are available for
adjusting batch effects when combining multiple gene
expression data sets. One recent study showed that simple
mean-centering can effectively remove many data set spe-
cific biases allowing effective integration of multiple data
sets [22]. Thus, we applied a simple mean-centering
method to the eight data sets and performed clustering
analysis to see if any data set specific batch effects are
observed in the pooled data set. No distinct batch effects
were found in the pooled data set (Figure 1), suggesting
that simple mean-centering was able to remove most, if
not all, batch-specific biases. Principal Component Anal-
ysis (PCA) of the pooled samples again confirmed that
batch effects were rarely found in the pooled data set
(Additional data file 1). The pool data set was used in the
subsequent analyses.
Increased sample size increases overlap between gene sets
We first calculated the degree of overlap between different
prognostic gene signatures as the sample size was varied.
An overlap between different prognostic gene signatures
increased according to the increased sample size (Figure
2). For example, the average overlap between data sets
with 100 samples was 1.33%, but it was increased to
16.56% with 600 samples. This number is in good agree-
ment with Ein-Dor et al. [12]'s prediction which suggested
that approximately five to eight hundred samples are
needed to attain an overlap of 20% in breast cancer data
sets.
Increased sample size decreases the error rate of class 
prediction
We then tested the effects of a sample size on the error rate
of class prediction which is the most important measure
of prognostic classifier performance in clinical decision
making [25,26]. For class prediction, each patient was
divided into good (relapse or distant metastasis free sur-
vival over five years) or poor (relapse or distant metastasis
within five years) prognosis groups. Relapse or metastasis
free patients followed up less than five years were
excluded from the analysis.
We applied random sampling approach in our evaluation
of error rate of class prediction by randomly selecting n
training samples (from 100 to 500 by an increment of
100) from the pooled data set, constructing a prognostic
classifier from the training samples, and evaluating its per-
formance on the 100 randomly selected testing samples
[9]. We used three well-established machine learning
algorithms – Diagonal Linear Discriminant Analysis
(DLDA), Support Vector Machine (SVM), and Random
Forest (RF) – in our analysis [27]. While SVM and RF algo-
rithms need fine tuning of several parameters to attain the
lowest error rate of prediction, we just applied default
parameters given in the R packages (e1071 for SVM andBMC Bioinformatics 2009, 10:147 http://www.biomedcentral.com/1471-2105/10/147
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RandomForest for RF) because we had to perform numer-
ous class predictions on several hundred data sets pre-
pared by re-sampling at each sample size.
The error rate of class prediction was decreased as the
number of training samples used for constructing prog-
nostic gene signatures increased (Figure 3) with all the
three algorithms producing similar results. The best aver-
age error rate was 34.66% obtained from the training sam-
ple size of 500 with support vector machine algorithm.
Concordance between predicted outcomes increases with 
an increasing training sample size
Recently, Fan et al. emphasized that concordance in the
predicted outcomes between different prognostic gene
signatures is the more relevant measure than the mere
overlap between them in evaluating the similarity
between different gene signatures [28]. We thus investi-
gated the effects of different training sample sizes on the
concordance in the predicted outcomes. For each sample
size, 100 samples were first left out as testing samples, and
n samples were randomly selected from the remaining
samples to produce a prognostic gene signature. The ran-
dom sampling process was repeated 100 times to produce
100 independent prognostic gene signatures. For each of
the 100 independently prepared prognostic gene signa-
ture, outcomes were predicted on the 100 initially left-out
testing samples and concordance in the predicted out-
comes among the 100 gene signatures were measured. As
expected, the concordance in the predicted outcomes
increased as the training sample size was increased (Figure
4). For example, the mean concordance was 83.3% at a
training sample size of 100, but it was increased to
91.16% with 200 training samples, and further increased
Pattern of clustering of 1,418 samples from eight data sets Figure 1
Pattern of clustering of 1,418 samples from eight data sets. Each data set was mean-centered and pooled into a single 
data set of 1,418 samples. Each color above the heatmap represents each data set.
E-TABM-158
GSE7378
GSE3494
GSE6532
GSE1456
GSE2603 GSE7390
GSE11121
Table 1: Data sets analyzed in this study
Data set Total ER+ ER- Survival Reference
GSE1456 159 99 40 RFS [13]
GSE2603 82 57 42 DMFS [14]
GSE3494 236 213 34 DMFS [15]
GSE6532 306 262 45 DMFS [16,17]
GSE7378 54 54 0 DMFS [18]
GSE7390 198 134 64 DMFS [19]
GSE11121 129 200 0 RFS [20]
E-TABM-158 344 84 46 DMFS [21]
Total 1418 1103 271BMC Bioinformatics 2009, 10:147 http://www.biomedcentral.com/1471-2105/10/147
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to 96.52% with 500 training samples. Similar patterns
were found with SVM and RF algorithms.
Sub-type specific gene signature decreases the prediction 
error rate
Recent studies have shown that breast cancer is a hetero-
geneous disease consisting of three to six different molec-
ular subtypes [29,30]. The estrogen receptor (ER) status is
one of the important molecular phenotypes in classifying
breast cancers into different subtypes [31]. Until now, to
increase the total sample size, we didn't divide samples
into different ER groups (ER-positive and ER-negative). To
see if sub-type specific analysis could improve the per-
formance of prognostic gene signatures, we first divided
samples into ER-positive and ER-negative groups and per-
formed analysis using only the ER-positive samples. ER-
negative sample specific analysis was not performed due
to the small number of ER-negative samples (Table 1).
With ER-positive samples, the number of training sample
was varied from 50 to 200 with an increment of 50. As
expected, analysis using only ER-positive samples always
produced lower error rates of prediction that the analysis
using both ER-positive and ER-negative samples did (Fig-
ure 5). For example, using DLDA algorithm, an average
prediction error rate of 35.92% was achieved by 200 sam-
ples in ER-positive specific analysis in comparison to an
average error rate of 38.71% in an analysis using both ER-
positive and ER-negative samples (P < 0.000224 by
unpaired t-test).
Discussion
Using more than 1,300 samples prepared by pooling eight
independent data sets, we explored the effects of a sample
size on three metrics: the degree of overlap between inde-
pendently developed gene signatures, the accuracy of out-
come prediction, and the degree of concordance in
outcome prediction between independently developed
gene signatures. We also tested if the accuracy of outcome
prediction could be further improved by sub-type specific
analysis. We found that all the three metrics were
improved by the increased sample size, but in different
degrees.
The degree of an overlap between independently devel-
oped gene signatures increased in proportion to the
number of training samples. With a sample size of 600, a
mean of 16.56% overlap was observed (Figure 2), which
is in good agreement with the results of Ein-Dor et al. who
showed that 500–800 samples are needed for 20% over-
lap and approximately 2000–3000 samples are needed for
50% overlap [12]. Thus, Ein-Dor et al.'s prediction is well
supported by a real gene expression data set in our analy-
sis. The same conclusion was obtained by Vliet et al. [32]
who showed that small sample size problem is the most
relevant explanation for the poor overlap between small-
sized data sets. The increased sample size will typically
increase overlap between independently developed gene
signatures by reducing variability between classifiers from
random sampling.
However, when we turned our focus on the concordance
in outcome prediction between different gene signatures,
we found that 200–300 samples were enough to achieve
reasonably good performance. For examples, with DLDA
algorithm, 91.16% and 94.61% concordant outcome pre-
dictions were achieved with 200 and 300 samples (Figure
3A), and similar results were obtained with RF and SVM
algorithms (Figure 3). The discrepancy between the degree
of overlap and the degree of concordance in outcome pre-
diction improved by increased sample size suggests that
the two measures of the performance of prognostic gene
signatures may be unrelated to each other [16,33]. Dob-
bin et al. recently emphasized that the identification of a
gene signature with optimal prediction accuracy should
be distinguished from the identification of a robust gene
An overlap between two prognostic gene-sets increases with  an increasing sample size Figure 2
An overlap between two prognostic gene-sets 
increases with an increasing sample size. From a data 
set of 1,372 samples, n samples were randomly selected and 
a prognostic gene set was prepared by selecting top 100 
genes with the lowest p-value from Cox proportional hazard 
survival analysis. The sample size n was varied from 100 to 
600 by an increment of 100, and the random sampling was 
performed 200 times for each sample size n. An overlap 
between two gene-sets was computed for each pair of 200 
prognostic gene sets and the distribution of the overlaps was 
shown as boxplots.
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The error rate of prediction decreases with an increasing training sample size Figure 3
The error rate of prediction decreases with an increasing training sample size. A. DLDA, B. RF, C. SVM. First, each 
sample was labeled as good (disease-free or overall survival over five years) or poor (recurrence or death within five years). 
Then, m training samples and 100 testing samples were randomly selected from the data set of pooled samples, a prognostic 
gene set was constructed from the m training samples, and its error rate of prediction was calculated by applying the prognos-
tic gene set to the 100 testing samples. The training sample size m was varied from 100 to 500 by an increment of 100, and the 
entire process was repeated 100 times. Three machine learning algorithms – DLDA, RF, and SVM – were used. Data repre-
sents a boxplot of error rates calculated by 100 random sampling processes.
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Concordance between predicted outcomes increases with an increasing training sample size Figure 4
Concordance between predicted outcomes increases with an increasing training sample size. For each sample 
size from 100 to 500 by increments of 100, one hundred samples were first selected as testing samples and 100 independently 
selected training samples were used to predict the outcomes of the already selected testing samples. Concordance of outcome 
prediction between each pair of 100 predictions (a total of 4950 pairs) was calculated. Three different algorithms (A. DLDA, B, 
RF, and C. SVM) were tested.
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Sub-type specific gene signature decreases the prediction error rate Figure 5
Sub-type specific gene signature decreases the prediction error rate. Estimation of prediction error rate by random 
sampling of training-testing samples was restricted to Estrogen-Receptor positive (ER+) samples, and its error rate (ER+ only) 
was compared with that of total (both ER+ and ER-) samples. A. ER+ samples by DLDA, B. Total samples by DLDA, C. ER+ 
samples by RF, D. Total samples by RF, E. ER+ samples by SVM, F. Total samples by RF.
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signature and that thousands of samples may not be
needed to produce a good classifier [20]. In another study,
Fan et al. showed that the lack of overlap between differ-
ent gene signatures may not be as serious a problem as
originally thought if different gene signatures are concord-
ant in their outcome prediction and represent similar bio-
logical processes and pathways [16,20]. That Ein-Dor et
al. could develop as many as eight independent, but
equally prognostic gene signatures from a single data set
gives another support for the view of putting little impor-
tance on the overlap between different signatures [11,21].
Because high-throughput gene expression data contain
enormous amounts of information and many genes are
co-regulated, it is comprehensible that many equally effi-
cient gene signatures can be developed from a single data
set [16,20].
Many morphologically similar tumors are heterogeneous
at the molecular level. For example, recent gene expres-
sion profiling studies have established that breast cancer
can be divided into three to six molecular subtypes by the
pattern of gene expression [29,30,34]. The ER status is the
most important molecular character to classify breast can-
cers into sub-types and many studies have shown that ER-
positive breast cancer is fundamentally different from ER-
negative one and should be treated differently [29,31]. For
this reason, we tested if developing prognostic gene signa-
tures in a sub-type specific manner could further improve
the prediction accuracy of a gene signature. Results
showed that about 3–5% improvement in prediction
accuracy is obtained by developing ER+ specific gene sig-
natures. Many recent works report the development of
ER+ or ER- specific gene signatures with much improved
performance [35,36].
We acknowledge that our work has several points for
improvement. First, survival information, which was arbi-
trarily dichotomized into binary outcomes for a class pre-
diction problem, may be used as a continuous variable for
its full use. Second, while we used only the ER-status var-
iable in our sub-type specific analysis of breast cancer data
sets, other clinical attributes such as node status, grade,
age, or treatment status should be considered as con-
founding factors in the analysis.
Conclusion
Increasing sample sizes generated a gene signature with
better stability, better concordance in outcome prediction,
and better prediction accuracy. However, the degree of
performance improvement by the increased sample size
was different between the degree of overlap and the degree
of concordance in outcome prediction. Thus, while thou-
sands of samples might be needed to achieve 50% or
more overlap, 200–300 samples were enough to achieve
between 90 and 95% concordance in outcome prediction.
Finally, sub-type specific analysis produced better results
suggesting that developing prognostic gene signatures for
specific patient sub-groups (i.e. ER-positive and negative
breast cancer patients, respectively) may be a better strat-
egy for heterogeneous diseases such as breast cancer.
Methods
Datasets and preprocessing of microarray data
Eight breast cancer gene expression data sets with clinical
information on patient survival and CEL files were
obtained from the Gene Expression Omnibus (GEO) [37]
or ArrayExpress [38]. See Table 1 for a complete list of data
sets and their sources. Only data sets generated using the
Affymetrix U133A platform were included. Each data set
was uniformly processed by RMA algorithm using the
downloaded CEL files, mean-centered, and then pooled
together into a single data set of 1,418 samples. Clustering
of the 1,418 samples was performed to see if there were
any batch effects among the eight combined data sets.
Then, 46 samples in which survival information is miss-
ing were excluded resulting in a total of 1,372 samples in
subsequent analyses.
Overlap between prognostic gene sets obtained from 
random sampling approach
From the data set of 1,372 samples, n samples were ran-
domly selected without replacement and a prognostic
gene set was built from the n samples by selecting top 100
genes with the lowest p-value from Cox proportional haz-
ard survival analysis. The sample size n was varied from
100 to 600 by an increment of 100 and the random sam-
pling was repeated 200 times for each sample size n. For
each sample size, an overlap between each pair of 200
prognostic gene sets was calculated [9].
Prediction accuracy
First, each patient was divided into good (relapse or dis-
tant metastasis free survival over five years) or poor
(relapse or distant metastasis within five years) prognosis
groups. Relapse or metastasis free patients followed up
less than five years were excluded from the analysis.
Three widely used machine learning algorithms, Diagonal
Linear Discriminant Analysis (DLDA), Support Vector
Machine (SVM), and Random Forest (RF), were used in
the analysis [15]. For each prognosis group, n training and
100 testing samples were randomly selected, a prognostic
predictor was constructed from the n training samples,
and its prediction accuracy was assessed by applying the
predictor on the 100 testing samples. For all the three
algorithms, genes differentially expressed between good
and poor prognosis groups (p < 0.001 by t-test) were first
selected and then used in the subsequent analyses. The
training sample size n was varied from 100 to 500 by an
increment of 100 and the random sampling was per-BMC Bioinformatics 2009, 10:147 http://www.biomedcentral.com/1471-2105/10/147
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formed 100 times for each sample size. An average of pre-
diction error rates from the 100 random sampling was
reported for each sample size. An equal number of sam-
ples were selected from the good and poor groups during
random sampling of a training-testing pair to avoid a bias
in error rate estimation that occurs when the sizes of two
classes are severely unbalanced. For the analysis of ER+
specific data set, the training sample size n was varied
from 50 to 200 by an increment of 50. The R statistical
programming language (version 2.6.2) [39] and Python
programming language (version 2.5.2) [40] were used for
statistical analyses and data manipulation, respectively.
The e1071 package (for SVM, version 1.5–18) and the ran-
domForest package (for RF, version 4.5–25) were
obtained from the comprehensive R archive network
(CRAN) website and the DLDA algorithms were imple-
mented using the Python programming language. To
briefly describe DLDA, it is relatively simple but efficient
linear rule based on the maximum likelihood discrimi-
nant rule [41]. In DLDA, a sample is assigned to a class k
in which
is minimized, where p is the number of genes, xj is the
value on gene j of the test sample,   is the sample mean
of class k and gene j, and σj
2 is the variance of the gene
[27]. For a brief description of SVM and RF, please see
Diaz-Uriarte et al., too [27]. For SVM, radial-basis kernel
with a gamma value of one over the number of columns
was used. For RF, the number of trees to grow was set to
200, cases were sampled with replacement, and mtry
(number of variables randomly selected as candidates at
each split) was set to square root of training sample size.
Analysis of the concordance in the outcome prediction
The effect of a sample size on the concordance in the out-
come prediction between different prognostic gene sets
was analyzed as follows. Five different sample sizes from
100 to 500 by an increment of 100 were used in the anal-
ysis. For each sample size, we first left out 100 testing sam-
ples from the total samples for outcome prediction. Then,
n training samples were randomly selected from the
remaining samples and used to produce prognostic gene
signatures. For each sample size, one hundred random
samplings were performed to produce 100 independent
prognostic gene signatures and each signature was used to
predict the outcomes of the left-out test samples at the first
step. The concordances in the predicted outcomes for each
pair among the 100 prognostic gene signatures were cal-
culated [16].
List of abbreviations used
GEO: Gene Expression Omnibus; GSE: Gene expression
Series; DLDA: Diagonal Linear Discriminant Analysis;
SVM: Support Vector Machine; RF: Random Forest;
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